Crescent Biopharma (CBIO) EBITDA Margin (2013 - 2026)

Crescent Biopharma (CBIO) reported EBITDA Margin of 2240.9% for Q1 2026, up 87.41% quarter-over-quarter from 17804.21% in Q2 2022.

Crescent Biopharma (CBIO) EBITDA Margin (2013 - 2026) Analysis & Trends

Crescent Biopharma (CBIO) has 8 years of EBITDA Margin data on file, last reported at 2240.9% in Q1 2026.

EBITDA Margin for Q1 2026 came in at 2240.9%, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was 15599.33% (changed N/A YoY), and the FY2025 annual result was 1419.61%, changed N/A from the prior year.
EBITDA Margin grew to 2240.9% in Q1 2026 per CBIO's latest filing, from 17804.21% in the prior quarter.
Over five years, EBITDA Margin peaked at 2240.9% in Q1 2026 and troughed at 17804.21% in Q2 2022.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-6.43%
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	38.10%
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Crescent Biopharma	486.92 Mn	297.76 Mn	-	-2,240.90%

Historic Data

Download Data

Date	Value
Mar 31, 2026	-2,240.90%
Jun 30, 2022	-17,804.21%
Dec 31, 2021	-98,870.20%
Sep 30, 2021	-20,028.82%
Jun 30, 2021	-10,144,001.41%
Mar 31, 2021	-1,352.98%
Dec 31, 2020	-9,554.94%
Sep 30, 2020	-1,372.73%
Mar 31, 2020	-90.09%
Sep 30, 2016	-42,631.11%
Dec 31, 2015	-25,123.75%
Sep 30, 2015	-20,272.43%
Jun 30, 2015	51.93%
Jun 30, 2014	53.66%
Dec 31, 2013	-4,995.73%
Sep 30, 2013	-7,039.81%
Jun 30, 2013	-6,349.56%
Mar 31, 2013	12.05%